NASDAQ:SAGE - SAGE Therapeutics Stock Price, Forecast & News

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

SAGE Therapeutics Inc (NASDAQ:SAGE) announced its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($3.48) earnings per share for the quarter, missing the Zacks' consensus estimate of ($3.41) by $0.07. The biopharmaceutical company earned $3.57 million during the quarter, compared to analysts' expectations of $2.52 million. SAGE Therapeutics had a negative return on equity of 60.00% and a negative net margin of 12,931.34%. SAGE Therapeutics's revenue for the quarter was up 35600.0% compared to the same quarter last year. During the same quarter last year, the company posted ($2.63) EPS. View SAGE Therapeutics' Earnings History.

SAGE Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for SAGE Therapeutics.

19 analysts have issued 12 month price objectives for SAGE Therapeutics' stock. Their forecasts range from $63.00 to $263.00. On average, they expect SAGE Therapeutics' share price to reach $127.00 in the next year. This suggests a possible upside of 80.2% from the stock's current price. View Analyst Price Targets for SAGE Therapeutics.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SAGE Therapeutics.

Media stories about SAGE stock have been trending very positive recently, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. SAGE Therapeutics earned a media sentiment score of 3.9 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for SAGE Therapeutics.

SAGE Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 7,050,000 shares, an increase of 15.6% from the December 15th total of 6,100,000 shares. Based on an average daily volume of 1,050,000 shares, the days-to-cover ratio is currently 6.7 days. Currently, 13.9% of the company's stock are sold short. View SAGE Therapeutics' Current Options Chain.

Some companies that are related to SAGE Therapeutics include Genmab A/S (GNMSF), GALAPAGOS NV/S (GLPG), Alnylam Pharmaceuticals (ALNY), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), Bausch Health Companies (BHC), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Amarin (AMRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Netflix (NFLX), Intercept Pharmaceuticals (ICPT), Advanced Micro Devices (AMD), GW Pharmaceuticals PLC- (GWPH), Sarepta Therapeutics (SRPT) and salesforce.com (CRM).

SAGE Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.10%), Clarius Group LLC (0.07%), Aurora Investment Managers LLC. (0.03%), Landsberg Bennett & Dubbaneh LLC (0.01%), Alpine Global Management LLC (0.01%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.

SAGE stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Nisa Investment Advisors LLC and Arthur M. Cohen & Associates LLC. Company insiders that have sold SAGE Therapeutics company stock in the last year include Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.

SAGE stock was acquired by a variety of institutional investors in the last quarter, including Clarius Group LLC, Rhenman & Partners Asset Management AB, Aurora Investment Managers LLC., Landsberg Bennett & Dubbaneh LLC and Alpine Global Management LLC. Company insiders that have bought SAGE Therapeutics stock in the last two years include Albert Robichaud and Jeffrey M Jonas. View Insider Buying and Selling for SAGE Therapeutics.

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SAGE stock can currently be purchased for approximately $70.46.

SAGE Therapeutics has a market capitalization of $3.65 billion and generates $90.27 million in revenue each year. The biopharmaceutical company earns $-372,880,000.00 in net income (profit) each year or ($8.08) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.View Additional Information About SAGE Therapeutics.

The official website for SAGE Therapeutics is http://www.sagerx.com/.

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]